4 transcripts
ITCI
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
is being developed for oncology indications and continues in a Phase I single ascending dose study in healthy volunteers.
Regarding ITI-333, our multiple
ITCI
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
-1020, is being developed for oncology indications. We are currently conducting a Phase I single ascending dose study with TI-1020 in healthy volunteers
ITCI
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
of 2025. With respect to our ITI-1020 oncology program, our Phase I single ascending dose study in healthy volunteers is progressing. Our earlier stage
ITCI
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
of different doses in healthy volunteers.
Lastly, we also have ongoing studies of ITI-333 for the treatment of opioid use disorder and pain. We have
- Prev
- 1
- Next